New York Assembly Bill A01869

New York 2025-2026 Regular Session

• Introduced: 1/14/25
• Refer: 1/14/25
• Refer: 1/7/26

Caption

Establishes a hyperbaric oxygen therapy pilot program to treat veterans suffering from traumatic brain injuries and post-traumatic stress disorder.

Summary

Bill A01869 establishes a hyperbaric oxygen therapy pilot program aimed at treating veterans diagnosed with traumatic brain injuries (TBI) or post-traumatic stress disorder (PTSD) in New York State. The program will be overseen by the commissioner of health and is set to last for five years. It allows authorized medical professionals to prescribe hyperbaric oxygen therapy, which must be administered in FDA-approved chambers. The bill also mandates annual reporting from participating providers regarding the program's cost and efficiency, culminating in a comprehensive report to state leadership by the end of 2031.

Impact

The implementation of this pilot program will amend the public health law in New York by introducing a new article specifically dedicated to hyperbaric oxygen therapy for veterans. This bill is expected to enhance treatment options for veterans suffering from TBI and PTSD, potentially improving their quality of life. It may also influence future healthcare policies regarding the treatment of mental health and brain injuries within the state.

Sentiment

The sentiment surrounding Bill A01869 appears to be generally supportive, particularly among veteran advocacy groups and healthcare providers who recognize the potential benefits of hyperbaric oxygen therapy. However, there may be some concerns regarding the efficacy and cost-effectiveness of such treatments, which could lead to discussions in committee meetings.

Contention

Notable points of contention may arise regarding the scientific validity and acceptance of hyperbaric oxygen therapy as a treatment for PTSD and TBI. Some healthcare professionals may question the appropriateness of prescribing this therapy, while advocates for veterans may push for its adoption as a necessary treatment option. The balance between innovative treatment approaches and established medical practices will likely be a key discussion point.